AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Current developments in perioperative ICI-based therapies for muscle-invasive bladder cancer indicate a shift toward more personalized and biomarker-driven treatment approaches in MIBC.
Muscle-invasive bladder cancer (MIBC) remains associated with high recurrence and mortality despite radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC). For decades, perioperative therapy was defined by platinum-based regimens, which improve survival but are limited to fewer than half of patients due...
Immunotherapy has changed the landscape of bladder cancer treatment in recent years, both for localized and metastatic bladder cancer. While bacillus Calmette–Guérin (BCG) remains the gold standard for high-risk non–muscle-invasive bladder cancer, the development of checkpoint inhibitors continues to increase treatment...
Radical surgery is the cornerstone of management for localized muscle-invasive urothelial carcinoma (MIUC), yet surgery alone cures only a proportion of patients because occult micrometastatic disease is common at diagnosis. Over the last two decades, perioperative systemic treatment has evolved from a cisplatin-based...
Adjuvant treatment of colorectal cancer (CRC) has traditionally been based on fluoropyrimidine- and oxaliplatin-based chemotherapy regimens, which remain the cornerstone of care for patients with resected stage III and selected high-risk stage II disease. However, despite substantial improvements in disease-free (DFS...
Research directions to make ovarian cancer more susceptible to immunotherapy are moving from empiric treatment to more biologically informed, multimodal approaches aimed at overcoming immune suppression, enhancing antitumor immunity, and personalizing treatment for patients with ovarian cancer.
Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for patients with gynecologic malignancies. ICIs have led to improved survival outcomes in uterine and cervical cancer, although with only modest success in ovarian cancer. In endometrial cancer, The Cancer Genome Atlas provided the framework f...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.